Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.13 USD | +1.18% | -7.24% | +82.03% |
Sales 2024 * | 604K 827K | Sales 2025 * | 8.03M 10.99M | Capitalization | 285M 390M |
---|---|---|---|---|---|
Net income 2024 * | -99M -135M | Net income 2025 * | -93M -127M | EV / Sales 2024 * | 472 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 35.5 x |
P/E ratio 2024 * |
-2.86
x | P/E ratio 2025 * |
-3.64
x | Employees | 122 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals, Inc.
1 day | +1.18% | ||
1 week | -7.24% | ||
Current month | -2.71% | ||
1 month | -4.21% | ||
3 months | +65.28% | ||
6 months | +156.37% | ||
Current year | +82.03% |
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 65 | 20-01-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 11.14 | +1.27% | 47 717 |
24-05-08 | 11 | -1.35% | 157,302 |
24-05-07 | 11.15 | -6.14% | 316,699 |
24-05-06 | 11.88 | -1.82% | 261,522 |
24-05-03 | 12.1 | +0.75% | 295,953 |
Delayed Quote Nasdaq, May 09, 2024 at 12:16 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+82.03% | 285M | |
+24.95% | 46.71B | |
+48.83% | 41.8B | |
-1.06% | 41.52B | |
-5.86% | 29.55B | |
+10.66% | 25.78B | |
-20.47% | 19.26B | |
+1.72% | 12.14B | |
-3.13% | 12.08B | |
+27.37% | 11.98B |
- Stock Market
- Equities
- INO Stock